Brian Lian - 02 Jan 2026 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Reporting relationship: President & CEO, Director
Issuer ticker: VKTX
Reported as of: 02 Jan 2026
Net transaction value: -$7,692,121
SEC form: 4
Accepted by SEC: 05 Jan 2026, 20:28:24 UTC
Prior SEC filing: 28 Oct 2025
Next SEC filing: 29 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Morneau, as Attorney-in-Fact

Key filing fact

Brian Lian filed Form 4 for Viking Therapeutics, Inc. (VKTX) on 05 Jan 2026.

Key facts

This page summarizes Brian Lian's Form 4 filing for Viking Therapeutics, Inc. (VKTX).
7 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2026, 20:28.

Change

Previous filing in this sequence was filed on 28 Oct 2025.
Current net transaction value: -$7,692,121.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001614578 Primary reporting owner

Lian Brian

Relationship: President & CEO, Director
Address: C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO
Signature: /s/ Michael Morneau, as Attorney-in-Fact
Signature date: 05 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VKTX transaction

Common Stock, par value $0.00001 per share

Award

Transaction value: $0
Shares: +78,400
Change %: +3.2%
Price: $0.000000
Shares after: 2,508,620
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F2

VKTX transaction

Common Stock, par value $0.00001 per share

Award

Transaction value: $0
Shares: +224,080
Change %: +8.9%
Price: $0.000000
Shares after: 2,732,700
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F3

VKTX transaction

Common Stock, par value $0.00001 per share

Sale

Transaction value: $4,277,032
Shares: -132,454
Change %: -4.8%
Price: $32.29
Shares after: 2,600,246
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F4, F5

VKTX transaction

Common Stock, par value $0.00001 per share

Sale

Transaction value: $1,778,267
Shares: -53,279
Change %: -2%
Price: $33.38
Shares after: 2,546,967
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F4, F6

VKTX transaction

Common Stock, par value $0.00001 per share

Sale

Transaction value: $1,412,399
Shares: -41,276
Change %: -1.6%
Price: $34.22
Shares after: 2,505,691
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F4, F7

VKTX transaction

Common Stock, par value $0.00001 per share

Sale

Transaction value: $224,423
Shares: -6,400
Change %: -0.26%
Price: $35.07
Shares after: 2,499,291
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F4, F8

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VKTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +176,300
Change %
Price: $0.000000
Shares after: 176,300
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 176,300
Exercise price: $35.42
Footnotes: F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.

Footnote F2

Includes 11,111 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.

Footnote F3

The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on January 2, 2026. upon the achievement of a non-financial performance goal and a second performance restricted stock unit award that was granted on January 3, 2025, 1.665% of which vested on January 2, 2026, upon the partial achievement of a non-financial performance goal.

Footnote F4

These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3.

Footnote F5

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.87 to $32.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F6

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.87 to $33.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F7

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F8

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Footnote F9

25% of the shares subject to the option will vest on each anniversary of the grant date.